United States Patent 7,781,577: Sotagliflozin Claims, Scope, Expiration and Patent Landscape
US Patent 7,781,577 covers a broad class of C-aryl glucoside and thioglucoside sodium-glucose cotransporter inhibitors, including sotagliflozin. The patent claims the active compound, pharmaceutical formulations, SGLT2 inhibition, glucose-lowering, urinary glucose excretion, insulin-sensitivity restoration and treatment of metabolic disease. Claim 25 is directed specifically to sotagliflozin.
The patent was issued on August 24, 2010. Its earliest priority date is generally reported as September 9, 2003, placing the ordinary 20-year patent term in the 2023-2024 period, subject to patent-term adjustment and any applicable regulatory extension. The patent no longer provides the principal forward-looking exclusivity barrier for sotagliflozin in the United States. FDA regulatory exclusivity and later method-of-use or formulation patents are more relevant to generic-entry timing.
What drug does US Patent 7,781,577 protect?
US 7,781,577 protects compounds in the C-aryl glucoside SGLT inhibitor class. The specifically identified compound in claim 25 is sotagliflozin, also known as LX4211.
| Item |
Information |
| Patent |
US 7,781,577 B2 |
| Technology |
C-aryl glucoside and thioglucoside SGLT inhibitors |
| Key active compound |
Sotagliflozin |
| Development code |
LX4211 |
| Commercial product |
Inpefa |
| Patent holder or originating company |
Lexicon Pharmaceuticals |
| Primary target |
SGLT2, with clinically relevant SGLT1 activity |
| FDA approval |
May 26, 2023 |
| FDA application |
NDA 214166 |
| Approved product |
Inpefa tablets |
| Principal U.S. indication |
Reduction of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in specified adults with heart failure or type 2 diabetes and chronic kidney disease |
| Patent issue date |
August 24, 2010 |
| Earliest reported priority date |
September 9, 2003 |
Sotagliflozin differs from dapagliflozin, empagliflozin and canagliflozin because its glucose-ring substituent contains a methylthio group. It also inhibits SGLT1, while the leading earlier commercial SGLT products were developed primarily as SGLT2 inhibitors.
What does claim 25 cover?
Claim 25 covers the specific compound:
"(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol"
This is the patent's compound claim for sotagliflozin, together with pharmaceutically acceptable salts.
The claim is structurally narrow compared with claims 1 and 6-8 because it identifies each major substituent:
- A chiral tetrahydropyran triol core;
- A 4-chloro-3-(4-ethoxybenzyl)phenyl substituent;
- A methylsulfanyl group at the 6-position;
- The specified stereochemical configuration;
- The free compound and pharmaceutically acceptable salts.
A product containing sotagliflozin as the same stereoisomer would fall within claim 25 if the claim remains enforceable. A different stereoisomer, a materially different substituent, or a non-equivalent glucoside analog would require analysis under other claims or under the doctrine of equivalents.
How broad are claims 1 through 8?
The principal compound claims use Markush definitions. Their scope extends beyond sotagliflozin to large groups of substituted aryl, heteroaryl, cycloalkyl and heterocyclic analogs.
Claim 1
Claim 1 covers a broad genus in which:
- R1 is an amino-derived substituent;
- R2 is fluoro or an oxygen-containing substituent;
- R6 and R7 may be hydrogen, halogen, hydroxyl, amino, cyano, nitro, alkyl, aryl, heterocycle or numerous carbonyl and sulfonyl derivatives;
- m and n are each 1 to 3.
This is a high-breadth composition-of-matter claim. It is potentially useful against analogs that differ from sotagliflozin at peripheral substituent positions but retain the claimed molecular architecture.
Claims 2 and 3 narrow claim 1 by requiring at least one R1A to be hydrogen or optionally substituted alkyl.
Claims 4 and 5
Claims 4 and 5 are separate compound genera with embedded structural formulas that were omitted from the supplied claim text. Their precise scope depends on those drawings or chemical structures. Claims 9-15 and 16-22 use claims 4 and 5 as the active-compound base.
These claims are important because they separately cover:
- Pharmaceutical formulations;
- SGLT2 inhibition;
- Blood-glucose reduction;
- Increased urinary glucose excretion;
- Restoration of insulin sensitivity;
- Treatment of diabetes, obesity, hypertension, cardiovascular disease, atherosclerosis, lipid disorders and metabolic syndrome.
Claim 6
Claim 6 covers a wider modular genus defined by:
- A and B as optionally substituted aryl, cycloalkyl or heterocyclic groups;
- Y as oxygen, sulfur, sulfoxide, sulfone, nitrogen, carbon chains or carbonyl-containing linkers;
- Multiple R1, R2, R3, R4 and R5 substituent options;
- Variable linker lengths.
This claim reaches beyond a single clinical molecule. It is a platform claim aimed at chemical classes with different ring systems and linkers.
Claims 7 and 8
Claims 7 and 8 cover additional compound subclasses involving:
- A substituted aryl, cycloalkyl or heterocyclic group;
- Fluoro or oxygen substitution;
- Acylated or non-acylated R8 groups;
- Sulfur, oxygen or nitrogen-containing R9 arrangements.
These claims may capture prodrugs, analogs and protected forms that differ from the active parent compound.
What do claims 9 through 24 protect?
Claims 9-24 are application and formulation claims built on the compound claims.
| Claims |
Subject matter |
| 9 |
Formulation containing a compound of claim 4 |
| 10 |
Inhibition of SGLT2 using a compound of claim 4 |
| 11 |
Lowering blood glucose using a compound of claim 4 |
| 12 |
Increasing urinary glucose excretion |
| 13 |
Restoring insulin sensitivity |
| 14 |
Treating listed metabolic and cardiovascular disorders |
| 15 |
Type 2 diabetes treatment under claim 14 |
| 16-22 |
Parallel formulation and treatment claims based on claim 5 |
| 23-24 |
Lower-alkyl limitations for R1A |
These claims are narrower than the broad chemical claims. Their practical value depends on whether the covered compound is used in the claimed formulation or for the specified method.
Does US 7,781,577 specifically claim sotagliflozin?
Yes. Claim 25 specifically claims sotagliflozin. Claim 26 covers a formulation containing sotagliflozin, and claim 27 covers treatment of type 2 diabetes using sotagliflozin.
Claims 25-27 are the clearest product-specific portion of the patent:
| Claim |
Scope |
| 25 |
Sotagliflozin or a pharmaceutically acceptable salt |
| 26 |
Pharmaceutical formulation containing sotagliflozin |
| 27 |
Treatment of type 2 diabetes using sotagliflozin |
The compound claim is generally stronger than the treatment claims because it does not require proof of a particular indication or clinical use. A commercial product containing the claimed active ingredient would present the most direct infringement issue while the claim remained enforceable.
When did US Patent 7,781,577 expire?
The patent's term is governed by the earliest effective U.S. filing date, not by the issue date. Based on the reported September 9, 2003 priority chain, the ordinary 20-year term fell in September 2023, before accounting for patent-term adjustment.
Public patent records commonly identify the patent's effective expiration in the 2024 period after applicable adjustment. The exact enforceability date requires the USPTO patent-term calculation, including:
- Patent-term adjustment;
- Continuation and divisional relationships;
- Terminal disclaimers;
- Any patent-term extension;
- Maintenance-fee status.
The patent should therefore be treated as an expired or near-expired primary composition patent by 2025, rather than as the main remaining barrier to a sotagliflozin generic.
What is the FDA exclusivity status of Inpefa?
FDA approved Inpefa on May 26, 2023. Sotagliflozin received new chemical entity exclusivity associated with the original approval. Five-year NCE exclusivity generally prevents submission of an ANDA or 505(b)(2) application relying on the listed drug for five years, subject to the Paragraph IV exception after four years under the Hatch-Waxman Act.
| FDA event |
Date |
| Inpefa approval |
May 26, 2023 |
| Four-year Paragraph IV submission threshold |
May 26, 2027 |
| Five-year NCE exclusivity endpoint |
May 26, 2028 |
NCE exclusivity is separate from patent protection. Even if US 7,781,577 has expired, an ANDA relying on Inpefa generally cannot be filed before the statutory NCE period ends, except where permitted through a Paragraph IV certification after the four-year point.
FDA Orange Book listings must be evaluated separately from the patent's historical claims. Listed patents can include later method-of-use, formulation, crystalline-form, manufacturing or other patents that were not part of US 7,781,577.
What later patents may protect sotagliflozin?
The commercial patent estate for Inpefa is likely to extend beyond the original compound patent. Later patent categories can include:
Formulation patents
These may cover:
- Tablet composition;
- Excipients and dissolution profiles;
- Stability-enhancing formulations;
- Specific dose strengths;
- Immediate-release delivery;
- Salt or solid-state forms.
A formulation patent is generally weaker against a generic that uses a materially different formulation, but it can still create an Orange Book certification issue if the generic product necessarily practices the claimed formulation.
Method-of-use patents
Sotagliflozin's commercial value shifted from diabetes development to heart-failure and chronic-kidney-disease outcomes. Later method claims may cover:
- Reducing heart-failure hospitalization;
- Treating heart failure;
- Treating patients with type 2 diabetes and chronic kidney disease;
- Reducing cardiovascular risk;
- Patient-selection criteria;
- Renal-function thresholds;
- Dosing schedules.
Method patents are vulnerable where a generic label omits the patented indication. They remain commercially relevant if the generic label includes the indication or if induced-infringement evidence supports a claim.
Manufacturing and process patents
Process patents may cover:
- Preparation of the chiral thioglucoside;
- Formation of the aryl-carbon bond;
- Control of stereochemistry;
- Purification;
- Crystallization;
- Salt formation;
- Removal of process impurities.
These patents generally do not block a generic unless the generic manufacturing process practices the claimed steps or the resulting product is subject to a product-by-process limitation.
What is the Paragraph IV risk for sotagliflozin?
The immediate generic-entry sequence is likely to be:
- NCE exclusivity blocks ordinary ANDA submission until May 26, 2028.
- A Paragraph IV ANDA may be submitted after May 26, 2027, assuming applicable statutory requirements are satisfied.
- A Paragraph IV notice could trigger patent litigation.
- Litigation could impose a 30-month stay on FDA approval under Hatch-Waxman.
- The first filer may seek 180-day generic exclusivity if statutory conditions are met.
The expired or expiring status of US 7,781,577 reduces the litigation value of the original composition claim. The principal risk would shift to later Orange Book-listed patents, especially indication, formulation and solid-state patents.
No biosimilar pathway applies. Sotagliflozin is a small-molecule drug, so competitive entry would occur through an ANDA or potentially a 505(b)(2) application, not through the abbreviated biologics pathway.
Which companies are challenging sotagliflozin?
The public record does not establish a major disclosed Paragraph IV litigation campaign against Inpefa comparable to the litigation surrounding older SGLT2 products. The most likely future challengers are generic manufacturers with experience in diabetes and cardiovascular drugs, including large ANDA filers and specialty generic companies.
A definitive competitor list requires current FDA Orange Book certifications, district-court filings and Paragraph IV notices. The original patent alone does not identify a current challenger.
What licensing deals affect the sotagliflozin patent estate?
Lexicon entered into a development and commercialization agreement with Sanofi for sotagliflozin. Sanofi exercised rights relating to the program but later returned rights after the program was discontinued in the diabetes setting. Lexicon subsequently retained control of sotagliflozin and pursued the heart-failure indication that led to Inpefa approval.
The commercial significance is twofold:
- Sanofi's prior involvement may explain portions of the development and patent history.
- Lexicon's later independent commercialization means current product revenue and U.S. patent strategy are primarily associated with Lexicon and Inpefa.
How strong is the patent estate for sotagliflozin?
The estate has strong historical composition-of-matter protection but weaker forward-looking protection from US 7,781,577 alone.
| Patent feature |
Assessment |
| Claim 25 compound protection |
Strong while enforceable |
| Broad Markush claims |
Potentially broad but subject to validity and written-description scrutiny |
| Formulation claims |
Moderate, depending on required excipients and product design |
| Diabetes method claims |
Limited commercial value after NCE and primary patent expiry |
| Heart-failure method claims |
Potentially important if Orange Book listed and included in generic labeling |
| Manufacturing claims |
Fact-specific and process-dependent |
| Biosimilar barrier |
Not applicable |
| Generic substitution risk |
Increasing after 2027-2028 |
Potential validity issues for broad claims include written description, enablement, anticipation, obviousness and claim-construction disputes. The specific sotagliflozin claim is generally easier to analyze than the broad genus claims because its structural limitations are expressly recited.
What generic launch scenarios exist?
Scenario 1: Launch after patent and exclusivity clearance
A generic applicant avoids or resolves listed patents and receives approval after NCE exclusivity expires. This is the cleanest entry route.
Scenario 2: Paragraph IV challenge
A first filer challenges later patents after May 26, 2027. The patent owner may sue within 45 days, creating a statutory approval stay of up to 30 months unless the case is resolved earlier.
Scenario 3: Skinny-label launch
A generic omits patented heart-failure or renal indications from its label and markets for unprotected indications. This strategy depends on the scope of the remaining method patents and the facts supporting induced infringement.
Scenario 4: 505(b)(2) entry
A sponsor could pursue a 505(b)(2) application for a different formulation, dosage form or use. This route would face reliance, patent certification and potential exclusivity issues.
What is the geographic coverage?
US 7,781,577 provides protection only in the United States. International protection would depend on counterpart applications and national grants in jurisdictions such as:
- Europe;
- Canada;
- Japan;
- Australia;
- China;
- South Korea;
- Brazil;
- India.
Foreign patent terms, claim scope, opposition outcomes and validity proceedings can differ materially from the U.S. case. The U.S. patent does not establish protection for sotagliflozin outside the United States.
Key Takeaways
- US 7,781,577 is a foundational Lexicon patent covering C-aryl glucoside SGLT inhibitors.
- Claim 25 specifically covers sotagliflozin.
- Claims 26 and 27 cover sotagliflozin formulations and type 2 diabetes treatment.
- Claims 1 and 6-8 are broad chemical Markush claims that extend beyond the marketed compound.
- The patent's original composition protection is expired or near expiration by 2025 based on the reported 2003 priority chain and applicable term adjustments.
- Inpefa received FDA approval on May 26, 2023.
- Five-year NCE exclusivity generally runs to May 26, 2028, with Paragraph IV filing potential after May 26, 2027.
- Later Orange Book-listed patents, particularly method-of-use and formulation patents, are more important than US 7,781,577 for future generic-entry analysis.
- Sotagliflozin is a small molecule and has no biosimilar pathway.
- The main commercial patent risk is likely to arise from later heart-failure, chronic-kidney-disease, formulation, solid-state and manufacturing patents.
FAQs
Is sotagliflozin the same drug as dapagliflozin?
No. Sotagliflozin and dapagliflozin are different SGLT inhibitors. Sotagliflozin contains a methylthio-substituted glucose-ring structure and has both SGLT1 and SGLT2 activity.
Does US 7,781,577 cover Inpefa?
Yes. Claim 25 specifically recites sotagliflozin, the active ingredient in Inpefa. Claim 26 covers formulations containing the compound, and claim 27 covers treatment of type 2 diabetes with it.
Can a generic launch immediately after US 7,781,577 expires?
Not necessarily. FDA NCE exclusivity, later Orange Book-listed patents and litigation stays can prevent approval or launch after the original composition patent expires.
Does a Paragraph IV challenge apply to an expired patent?
A Paragraph IV certification is generally directed to a listed patent that the applicant believes is invalid, unenforceable or not infringed. An expired patent ordinarily does not provide a continuing injunction against launch, but the complete Orange Book listing and certification record control the analysis.
Are sotagliflozin manufacturing patents commercially important?
They can be. A manufacturing patent may create litigation risk if a generic uses the claimed synthesis, stereochemical resolution, purification or crystallization process. Its practical value depends on the generic's actual process and the patent's enforceability.
References
- U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,781,577, C-aryl glucoside compounds and methods of use thereof.
- U.S. Food and Drug Administration. (2023). Inpefa prescribing information: Sotagliflozin tablets.
- U.S. Food and Drug Administration. (2023). Drugs@FDA: Inpefa, NDA 214166.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- Lexicon Pharmaceuticals, Inc. (2023). Annual report on Form 10-K for the fiscal year ended December 31, 2022.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.